1. Trial at a Glance
APOLLO is a recruiting clinical trial evaluating transcatheter mitral valve replacement with the Medtronic Intrepid TMVR System in patients with severe symptomatic mitral regurgitation.
| Feature | APOLLO |
|---|---|
| Condition | Mitral Valve Regurgitation |
| Design | Non-randomized, single-group |
| Masking | None |
| Primary purpose | Treatment |
| Lead sponsor | Medtronic Cardiovascular |
| Sponsor type | Industry |
| Intervention | Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) |
2. Clinical Question
Population
Patients with severe symptomatic mitral regurgitation.
Intervention
Medtronic Intrepid Transcatheter Mitral Valve Replacement System.
Comparator
No randomized comparator; the registry describes a single-group design.
Primary question
How does treatment with the Intrepid TMVR System perform according to the prespecified 1-year primary endpoints?
3. Trial Design
Non-randomized
Single group
None
2 registered arms with the same device intervention description
4. Endpoints
| Endpoint | Time frame | Description |
|---|---|---|
| Primary Cohort | 1 year | Composite of all-cause mortality or heart failure hospitalization |
| MAC Cohort | 1 year | All-cause mortality |
5. Planned Analysis
The ClinicalTrials.gov record does not contain posted results for APOLLO. The registry identifies the primary outcomes that will be evaluated at 1 year, but no statistical estimates, confidence intervals, or p-values are posted.
For a composite endpoint such as all-cause mortality or heart failure hospitalization, a typical analysis evaluates the time from treatment to the first occurrence of either component event. Statistical approaches commonly include time-to-event methods that account for patients who have not experienced an event during follow-up through censoring. Interpretation requires attention to the contribution of each component because a composite endpoint may be influenced more strongly by one component than another.
For an all-cause mortality endpoint, statistical evaluation generally focuses on the time until death from any cause. The choice of analysis framework depends on the prespecified statistical analysis plan, including definitions of analysis populations, censoring rules, and event handling.
6. Statistical Methodology
Composite endpoints
A composite endpoint combines multiple clinically relevant outcomes into one analysis. The combined measure can increase the number of observed events, but interpretation depends on whether the individual components are similarly important and similarly affected.
Time-to-event analysis
Time-to-event methods are designed for outcomes where both whether an event occurs and when it occurs are important. Patients without an observed event by the end of follow-up contribute information until their censoring time.
7. Statistical Methods Explained
Why use a composite endpoint?
A composite can capture more total events, but each component must be interpreted separately to understand the clinical meaning of the overall result.
Why does a single-group design matter?
Without randomization or a concurrent comparator, observed outcomes are interpreted differently from a randomized treatment comparison.
Why are confidence intervals important?
Confidence intervals describe uncertainty around an estimate and provide context beyond a single numerical result.
Why is follow-up time important?
The 1-year endpoint definitions specify the time horizon for evaluating the primary outcomes.
8. Limitations
- The ClinicalTrials.gov record does not report efficacy estimates, confidence intervals, or p-values.
- The registry describes a non-randomized, single-group design, limiting direct randomized comparisons.
- Interpretation of composite endpoints requires understanding the contribution of each component outcome.
- Device studies require attention to procedural, follow-up, and endpoint definitions when interpreting results.
9. Why This Trial Matters Statistically
APOLLO illustrates several important principles in clinical-trial methodology: prospective endpoint definition, analysis of device interventions, composite outcomes, mortality endpoints, and the distinction between single-group evidence and randomized comparative evidence.
| Concept | Role in APOLLO |
|---|---|
| Composite endpoint | Primary Cohort endpoint combines mortality and heart failure hospitalization |
| Time frame | Primary endpoints assessed at 1 year |
| Single-group design | Non-randomized evaluation |
| Clinical endpoint definition | Prespecified outcome assessment |